# USE OF PSYCHOTROPIC DRUGS IN CHILDREN AND ADOLESCENTS IN CATALONIA. A cohort study with real world data from the electronic primary health care record from 2007-2017. (PEPSICAT)

**First published:** 22/02/2019

**Last updated:** 14/03/2024

Study  Ongoing

## Administrative details

**EU PAS number**

EUPAS28375

**Study ID**

28503

**DARWIN EU® study**

No

**Study countries**

Spain

**Study description**

This project has four main objectives: to describe in children <18 years the use of psychotropic drugs during the last decade, to describe their psychiatric diagnoses, to describe the baseline characteristics when starting treatment with psychotropic drugs and, to describe the consumption pattern of psychotropic drugs. As secondary objectives: to analyse factors associated with the use of different psychotropic drugs and factors related to the diagnosis of mental illness in patients under treatment with psychotropic drugs and to describe the adherence to psychotropic treatment. As exploratory objectives, an attempt will be made to correlate the maternal obstetric and psychiatric history with the consumption of psychotropic medication in the offspring and to analyse the reasons for the lack of a diagnostic record of mental pathology in patients with psychotropic treatment. Methods: Descriptive observational study will from 2007-2017 in the population under the age of 18 with at least one prescription for a psychotropic drug. Two studies will be carried out: one to estimate the prevalence of psychotropic drug use and psychiatric pathology diagnoses and the second one to estimate the incidence of psychotropic drug use in the <18 year population. This population will be followed until the end of the study or the impossibility to obtain information (death/transfer). The treatment period with this first psychotropic drug and the addition of other psychotropic drugs or the change of psychotropic treatment will be analysed during the follow-up. Data source: SIDIAP (Sistema de Información para el Desarrollo de la Investigación en Atención Primaria) database, which contains anonymized clinical information on approximately 80% of the population of Catalonia (Spain). Information will be completed with data from the Basic Minimum Data Set for outpatient mental health care (CMBD-SMA). Data will be stratified by sex and age groups.

**Study status**

Ongoing

# Research institutions and networks

# Institutions

## Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

☐ Spain

**First published:** 05/10/2012

**Last updated:** 23/05/2025

`Institution`  `Educational Institution`  `Laboratory/Research/Testing facility`

`Not-for-profit`  `ENCePP partner`

# Contact details

**Study institution contact**

Ainhoa Gome-Lumbreras agomez@idiapjgol.info

`Study contact`

[agomez@idiapjgol.info](mailto:agomez@idiapjgol.info)

**Primary lead investigator**

Gomez-Lumbreras Ainhoa

`Primary lead investigator`

# Study timelines

**Date when funding contract was signed**

Planned: 16/02/2018

**Study start date**

Planned: 01/06/2018

Actual: 01/06/2018

**Data analysis start date**

Planned: 14/06/2018

**Date of interim report, if expected**

Planned: 05/10/2018

Actual: 05/10/2018

**Date of final study report**

Planned: 31/12/2020

# Sources of funding

- Other

# More details on funding

Catalan Health Department

# Study protocol

PEPSICAT_ENCePP.pdf(283.36 KB)

# Regulatory

**Was the study required by a regulatory body?**

No

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

# Other study registration identification numbers and links

Catalan Health Department
SLT006/17/00309https://web.gencat.cat/web/shared/OVT/Departaments/SLT/Documents/F
definitiva-de-concessio-de-la-subencio-PERIS-2018-2020.pdfAEMPS
classification: EPA-OD. UMO 2007-17. Code: IUI-FLU-2018-01

# Methodological aspects

# Study type

# Study type list

**Study type:**

Non-interventional study

**Scope of the study:**

Drug utilisation

**Main study objective:**

To describe the use of psychotropic drugs in children <18 years from Catalonia during 2007-2017.To describe the psychiatric diagnoses in the <18 years population consuming psychotropic drugs.To describe the consumption pattern and characteristics of patients <18 years who start treatment with psychotropic drugs.

# Study Design

**Non-interventional study design**

Cohort

# Study drug and medical condition

**Anatomical Therapeutic Chemical (ATC) code**

(N06BA) Centrally acting sympathomimetics

Centrally acting sympathomimetics

(N06A) ANTIDEPRESSANTS

ANTIDEPRESSANTS

(N05A) ANTIPSYCHOTICS

ANTIPSYCHOTICS

(N05B) ANXIOLYTICS

ANXIOLYTICS

(N05C) HYPNOTICS AND SEDATIVES

HYPNOTICS AND SEDATIVES

---

**Medical condition to be studied**

Psychiatric investigation

# Population studied

**Age groups**

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

**Estimated number of subjects**

300000

# Study design details

**Data analysis plan**

All data management, purification, descriptive calculation and statistical analysis processes will be carried out using the statistical package R 3.3(2016)Demographic data and baseline characteristics of the population will be described by relative and absolute frequencies for the categorical variables and median standard deviation or median and interquartile range for the continuous variables.In the bivariate analysis, Chi-square test or the exact Fischer test for the categorical variables and the t-test of Student or the U-test of Mann-Whitney for the continuous variables according to their distributionEvaluation of psychotropic consumption based on psychiatric/obstetric maternal records, as well as the risk related to the persistence/adherence of these in patients with an age range of 16 to 18 years old, will be performed using multiple logistic regression models or proportional risk models (Cox).Adjustment for risk factors based on the characteristics of the study population

# Data management

# ENCePP Seal

# Data sources

**Data source(s)**

The Information System for Research in Primary Care (SIDIAP)

**Data source(s), other**

SIDIAP

**Data sources (types)**

Administrative healthcare records (e.g., claims)

Drug dispensing/prescription data

Electronic healthcare records (EHR)

# Use of a Common Data Model (CDM)

**CDM mapping**

No

# Data quality specifications

**Check conformance**

Unknown

**Check completeness**

Unknown

**Check stability**

Unknown

**Check logical consistency**

Unknown

# Data characterisation

**Data characterisation conducted**

No